Detailed reasons for delay in submission of unaudited financial results (Standalone & consolidated) for the quarter ended 31 st December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Indrayani Biotech has informed BSE that it will not meet the 14 February 2026 deadline to file its unaudited standalone and consolidated financial results for the quarter ended 31 December 2025, as required under SEBI LODR Regulation 33. The company stated that the audit process is still ongoing and results will be filed once the audit is completed. The company also reminded that the trading window for designated persons remains closed until 48 hours after the results are declared. No financial figures, revenue details, or profit/loss numbers have been disclosed in this filing — it is purely a delay-related intimation.
Shareholders should note that Q3 FY26 results are delayed and the actual numbers are not yet available, which may create short-term uncertainty around the stock. Continued delay in filings or audit issues could attract regulatory scrutiny from BSE/SEBI and may dent investor confidence.